JP2019517267A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517267A5 JP2019517267A5 JP2018564239A JP2018564239A JP2019517267A5 JP 2019517267 A5 JP2019517267 A5 JP 2019517267A5 JP 2018564239 A JP2018564239 A JP 2018564239A JP 2018564239 A JP2018564239 A JP 2018564239A JP 2019517267 A5 JP2019517267 A5 JP 2019517267A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- domain
- her1t
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- 210000004027 cell Anatomy 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 35
- 230000011664 signaling Effects 0.000 claims description 35
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 33
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 33
- 150000007523 nucleic acids Chemical group 0.000 claims description 32
- 108020004707 nucleic acids Proteins 0.000 claims description 24
- 102000039446 nucleic acids Human genes 0.000 claims description 24
- 239000012642 immune effector Substances 0.000 claims description 21
- 229940121354 immunomodulator Drugs 0.000 claims description 21
- 230000000139 costimulatory effect Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 20
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims description 19
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims description 19
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 17
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 17
- 102000001301 EGF receptor Human genes 0.000 claims description 15
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 15
- 108060006698 EGF receptor Proteins 0.000 claims description 10
- 240000007019 Oxalis corniculata Species 0.000 claims description 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 239000013603 viral vector Substances 0.000 claims description 7
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 6
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 6
- 102000008579 Transposases Human genes 0.000 claims description 6
- 108010020764 Transposases Proteins 0.000 claims description 6
- 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 claims description 5
- 101100118549 Homo sapiens EGFR gene Proteins 0.000 claims description 5
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 5
- 241000713666 Lentivirus Species 0.000 claims description 5
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 5
- 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 claims description 5
- 241001430294 unidentified retrovirus Species 0.000 claims description 5
- 241000700605 Viruses Species 0.000 claims description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 101150090033 DRB2 gene Proteins 0.000 claims description 3
- 101100117568 Oryza sativa subsp. japonica DRB5 gene Proteins 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 102000000588 Interleukin-2 Human genes 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 claims description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims 3
- 238000010361 transduction Methods 0.000 claims 3
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 claims 1
- 230000021633 leukocyte mediated immunity Effects 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110311A JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347503P | 2016-06-08 | 2016-06-08 | |
| US62/347,503 | 2016-06-08 | ||
| PCT/US2017/036440 WO2017214333A1 (en) | 2016-06-08 | 2017-06-07 | Cd33 specific chimeric antigen receptors |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110311A Division JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A Division JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517267A JP2019517267A (ja) | 2019-06-24 |
| JP2019517267A5 true JP2019517267A5 (https=) | 2020-07-09 |
| JP7591342B2 JP7591342B2 (ja) | 2024-11-28 |
Family
ID=59071136
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018564239A Active JP7591342B2 (ja) | 2016-06-08 | 2017-06-07 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2022110311A Withdrawn JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A Pending JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110311A Withdrawn JP2022153434A (ja) | 2016-06-08 | 2022-07-08 | Ｃｄ３３特異的キメラ抗原受容体 |
| JP2024097538A Pending JP2024138280A (ja) | 2016-06-08 | 2024-06-17 | Ｃｄ３３特異的キメラ抗原受容体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11787848B2 (https=) |
| EP (1) | EP3468994A1 (https=) |
| JP (3) | JP7591342B2 (https=) |
| KR (3) | KR102469703B1 (https=) |
| CN (2) | CN118652336A (https=) |
| AU (2) | AU2017279548B2 (https=) |
| CA (1) | CA3025667A1 (https=) |
| IL (2) | IL263220B2 (https=) |
| SG (1) | SG11201810640RA (https=) |
| WO (1) | WO2017214333A1 (https=) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3143134T3 (da) | 2014-05-15 | 2021-01-04 | Nat Univ Singapore | Modificerede, naturlige dræberceller og anvendelser deraf |
| CA3025667A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
| RU2019130504A (ru) | 2017-02-28 | 2021-03-30 | Вор Байофарма, Инк. | Композиции и способы ингибирования линиеспецифических белков |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| BR112019019917A2 (pt) | 2017-03-27 | 2020-04-22 | Nat Univ Singapore | receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais |
| CA3065930A1 (en) | 2017-06-07 | 2018-12-13 | Intrexon Corporation | Expression of novel cell tags |
| US11771718B2 (en) * | 2017-10-18 | 2023-10-03 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| US12053490B2 (en) * | 2017-10-26 | 2024-08-06 | St. Jude Children's Research Hospital, Inc. | Methods and compositions for treating CD33+ cancers and improving in vivo persistence of chimeric antigen receptor T cells |
| EP3720559A4 (en) * | 2017-12-04 | 2021-10-06 | Actinium Pharmaceuticals, Inc. | METHODS OF TREATMENT OF PATIENTS WITH MYELODYSPLASIC SYNDROMES |
| EP3749685A4 (en) | 2018-02-09 | 2021-12-22 | National University of Singapore | ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY |
| CA3089167A1 (en) * | 2018-02-09 | 2019-08-15 | National University Of Singapore | Adhesion receptor constructs and uses thereof in natural killer cell immunotherapy |
| US20200399383A1 (en) * | 2018-02-13 | 2020-12-24 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| CA3091224A1 (en) | 2018-03-12 | 2019-09-19 | Nantkwest, Inc. | Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity) |
| EA202092044A1 (ru) * | 2018-03-14 | 2021-03-03 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные рецепторы антигена против cd33 и их применения |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| US11319380B2 (en) * | 2018-06-04 | 2022-05-03 | Precigen, Inc. | MUC16 specific chimeric antigen receptors and uses thereof |
| EP3801570A4 (en) * | 2018-06-05 | 2022-04-20 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | ARTIFICIAL ANTIGEN PRESENTATION CELLS WITH PROTEIN L FOR EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY |
| US20210236547A1 (en) * | 2018-06-05 | 2021-08-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Rapid production, expansion, and increased purity of car-t cells using beads with protein l |
| CN110615842B (zh) * | 2018-06-20 | 2023-05-09 | 上海隆耀生物科技有限公司 | 一种包含共刺激受体的嵌合抗原受体及应用 |
| CN110699318A (zh) * | 2018-07-09 | 2020-01-17 | 广西慧宝源健康产业有限公司 | T细胞培养基及培养方法 |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| CN110862967A (zh) * | 2018-08-27 | 2020-03-06 | 天津天锐生物科技有限公司 | 一种不依赖细胞因子培养的自然杀伤细胞系silk-nk |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| EP3844186A4 (en) | 2018-08-29 | 2022-08-17 | National University of Singapore | METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS |
| CN113416251B (zh) * | 2018-09-26 | 2022-05-17 | 重庆精准生物技术有限公司 | 抗cd123人源化单链抗体及其应用 |
| WO2020077180A1 (en) * | 2018-10-11 | 2020-04-16 | Nantcell, Inc. | Treatment of immunosuppressed subjects |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| CN113613725B (zh) * | 2018-11-05 | 2025-09-23 | 路德维格癌症研究所有限公司 | 人源化和变体TGF-β1特异性抗体及其方法和用途 |
| CA3120563A1 (en) | 2018-11-26 | 2020-06-04 | Nkarta, Inc. | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy |
| CN109735558B (zh) * | 2018-12-12 | 2022-04-15 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
| WO2020123947A1 (en) | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN111378046B (zh) * | 2018-12-27 | 2024-03-15 | 上海细胞治疗集团有限公司 | 一种免疫效应细胞转换受体 |
| US12101761B2 (en) | 2019-01-10 | 2024-09-24 | Sony Group Corporation | Communications devices, methods of operating communications devices, infrastructure equipment and methods |
| CN114502188B (zh) * | 2019-02-21 | 2025-04-04 | 艾贝乐医药科技有限公司 | 人工免疫监视嵌合抗原受体及其表达细胞 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| SG11202111031RA (en) * | 2019-04-26 | 2021-11-29 | Allogene Therapeutics Inc | Rituximab-resistant chimeric antigen receptors and uses thereof |
| TW202110873A (zh) * | 2019-04-30 | 2021-03-16 | 美商聖堤生物科技股份有限公司 | 嵌合受體及其使用方法 |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| EP4032972A4 (en) * | 2019-09-18 | 2024-07-24 | Slbigen Inc. | GENETICALLY MODIFIED NK CELL LINE TRANSDUCED WITH A GENE ENCODING A NEW CHIMERIC ANTIGEN RECEPTOR AND ITS USE |
| EP4065157A1 (en) | 2019-11-26 | 2022-10-05 | Novartis AG | Cd19 and cd22 chimeric antigen receptors and uses thereof |
| KR20220142433A (ko) | 2020-01-17 | 2022-10-21 | 사나 바이오테크놀로지, 인크. | 유전자 발현 조절용 안전 스위치 |
| CN115916963A (zh) | 2020-03-27 | 2023-04-04 | 门德斯有限公司 | 白血病来源的经修饰细胞用于增强过继性细胞治疗的效力的离体用途 |
| CN115348973A (zh) * | 2020-03-31 | 2022-11-15 | 弗莱德哈钦森癌症中心 | 靶向cd33的嵌合抗原受体 |
| EP4171617A1 (en) | 2020-06-30 | 2023-05-03 | Mendus B.V. | Use of leukemia-derived cells in ovarian cancer vaccines |
| KR20230040364A (ko) * | 2020-07-27 | 2023-03-22 | 센터 포 엑설런스 인 몰레큘러 셀 사이언스, 차이니즈 아카데미 오브 사이언시스 | 키메라 항원 수용체 및 이의 용도 |
| TW202216990A (zh) * | 2020-09-08 | 2022-05-01 | 中國大陸商亘喜生物科技（上海）有限公司 | 用於ｔ細胞工程化的組合物和方法 |
| MX2023004811A (es) * | 2020-10-26 | 2023-06-29 | Res Institute At Nationwide Children´S Hospital | Células nk del receptor de antígeno quimérico (car) y usos de las mismas. |
| CA3196677A1 (en) | 2020-11-05 | 2022-05-12 | Erik Hans MANTING | Use of tumor-independent antigens in immunotherapies |
| CN116648457A (zh) * | 2020-12-31 | 2023-08-25 | 亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫细胞中的应用 |
| JP2024506249A (ja) | 2021-01-22 | 2024-02-13 | メンドゥス・ベスローテン・フェンノートシャップ | 腫瘍ワクチン接種の方法 |
| WO2022174172A1 (en) * | 2021-02-15 | 2022-08-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Customized chimeric antigen receptor polypeptides |
| TW202307210A (zh) | 2021-06-01 | 2023-02-16 | 瑞士商諾華公司 | Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途 |
| US20240358761A1 (en) | 2021-08-11 | 2024-10-31 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| EP4384598A1 (en) | 2021-08-11 | 2024-06-19 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
| AU2022325232A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified primary cells for allogeneic cell therapy |
| JP2024535677A (ja) | 2021-08-11 | 2024-10-02 | サナ バイオテクノロジー，インコーポレイテッド | 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞 |
| CN115724969A (zh) * | 2021-08-27 | 2023-03-03 | 合肥瀚科迈博生物技术有限公司 | Lag-3结合分子及其应用 |
| AU2023212736A1 (en) * | 2022-01-25 | 2024-08-01 | Sunshine Lake Pharma Co., Ltd. | Viral vector and application thereof |
| WO2023150674A2 (en) * | 2022-02-04 | 2023-08-10 | Duke University | Compositions for and methods of effecting tumor cell death |
| US20250302953A1 (en) | 2022-02-14 | 2025-10-02 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| EP4479416A1 (en) | 2022-02-17 | 2024-12-25 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
| WO2023173123A1 (en) | 2022-03-11 | 2023-09-14 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| EP4514829A1 (en) * | 2022-04-28 | 2025-03-05 | Immatics US, Inc. | Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2024097313A1 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods for producing t cell therapy products |
| JP2025540894A (ja) * | 2022-11-29 | 2025-12-16 | マルコープ・バイオディスカバリーズ・リミテッド | 新規ｃｄ２０タンパク質 |
| CN116789837B (zh) * | 2023-03-24 | 2024-02-23 | 山西纳安生物科技股份有限公司 | 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用 |
| WO2024218688A1 (en) * | 2023-04-18 | 2024-10-24 | Board Of Regents, The University Of Texas System | Bcma chimeric antigen receptors and uses thereof |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| EP4716541A2 (en) | 2023-05-22 | 2026-04-01 | Sana Biotechnology, Inc. | Methods of delivery of islet cells and related methods |
| WO2025054202A1 (en) | 2023-09-05 | 2025-03-13 | Sana Biotechnology, Inc. | Method of screening a sample comprising a transgene with a unique barcode |
| CN119613562A (zh) * | 2023-09-14 | 2025-03-14 | 重庆精准生物技术有限公司 | 细胞因子融合蛋白及其应用 |
| CN117587014B (zh) * | 2023-11-24 | 2025-01-24 | 上海恩凯细胞技术有限公司 | 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用 |
| WO2025151838A1 (en) | 2024-01-12 | 2025-07-17 | Sana Biotechnology, Inc. | Safety switches to control in vitro and in vivo proliferation of cell therapy products |
| WO2025202213A1 (en) | 2024-03-26 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Lipid nanoparticle loaded with antitumoral agent and functionnalized to target immosuppressive cells |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6218525B1 (en) * | 1988-02-25 | 2001-04-17 | The General Hospital Corporation | Nucleic acid encoding CD28 |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6007814A (en) | 1992-06-15 | 1999-12-28 | Sloan-Kettering Institute For Cancer Research | Therapeutic uses of the hypervariable region of monoclonal antibody M195 and constructs thereof |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| CA2214649C (en) | 1995-03-08 | 2007-06-12 | Zeling Cai | Antigen presenting system and methods for activation of t-cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| ES2278390T3 (es) | 1996-05-23 | 2007-08-01 | The Scripps Research Institute | Sistema de presentacion de antigenos de clase ii de cmh y procedimientos de activacion de linfocitos t cd4+. |
| ATE466948T1 (de) | 1997-03-11 | 2010-05-15 | Univ Minnesota | Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle |
| US6790662B1 (en) | 1999-03-12 | 2004-09-14 | Ortho-Mcneil Pharmaceutical, Inc. | Method of isolating CD8+ cells, and related hybridoma cells antibodies and polypeptides |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
| AU2001249315A1 (en) | 2000-03-22 | 2001-10-03 | Rheogene, Inc. | Ecdysone receptor-based inducible gene expression system |
| AU2001275474A1 (en) | 2000-06-12 | 2001-12-24 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
| JP4955904B2 (ja) | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | 新規エクジソン受容体／無脊椎動物レチノイドｘ受容体−ベースの誘導性遺伝子発現システム |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| EP1373470B1 (en) | 2001-02-20 | 2013-04-24 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| EP1534738B1 (en) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2002066614A2 (en) | 2001-02-20 | 2002-08-29 | Rheogene Holdings, Inc. | Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system |
| US7919269B2 (en) | 2001-09-26 | 2011-04-05 | Intrexon Corporation | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
| MXPA04002810A (es) | 2001-09-26 | 2005-06-06 | Rheogene Holdings Inc | Acidos nucleicos receptores de ecdisona de saltarilla, polipeptidos, y sus usos. |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2003089618A2 (en) | 2002-04-22 | 2003-10-30 | Regents Of The University Of Minnesota | Transposon system and methods of use |
| US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
| WO2005118788A2 (en) | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| GB0523954D0 (en) | 2005-11-24 | 2006-01-04 | Ucb Celltech | Bioassays |
| CA2643337C (en) | 2006-03-01 | 2016-01-12 | Janssen Pharmaceutica N.V. | Cancer treatment combining lymphodepleting agent with ctls and cytokines |
| JP5543207B2 (ja) | 2006-10-04 | 2014-07-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 不活性化された人工抗原提示細胞の調製および細胞治療におけるそれらの使用 |
| US20090075378A1 (en) | 2007-02-20 | 2009-03-19 | Anaptysbio, Inc. | Somatic hypermutation systems |
| EP2160461B1 (en) | 2007-07-04 | 2012-08-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Hyperactive variants of the transposase protein of the transposon system sleeping beauty |
| MX2010003371A (es) | 2007-09-28 | 2010-05-05 | Intrexon Corp | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. |
| BRPI0818287A2 (pt) | 2007-10-08 | 2015-11-03 | Intrexon Corp | células dendríticas manipuladas e usos para o tratamento do câncer. |
| WO2009054917A1 (en) | 2007-10-19 | 2009-04-30 | Amgen Inc. | Methods of selecting epidermal growth factor receptor (egfr) binding agents |
| RU2573912C2 (ru) | 2008-10-08 | 2016-01-27 | Интрексон Корпорейшн | Сконструированные клетки, экспрессирующие множественные иммуномодуляторы, и их применения |
| TR201904484T4 (tr) | 2009-11-03 | 2019-05-21 | Hope City | Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt). |
| KR20130010121A (ko) | 2010-03-23 | 2013-01-25 | 인트렉손 코포레이션 | 치료적 단백질을 조건부로 발현하는 벡터，상기 벡터를 포함하는 숙주 세포 및 이의 용도 |
| EA201390472A1 (ru) | 2010-10-29 | 2014-02-28 | Иммьюноджен, Инк. | Новые молекулы, связывающиеся с egfr, и их иммуноконъюгаты |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP6189754B2 (ja) | 2011-03-04 | 2017-08-30 | イントレキソン コーポレーション | タンパク質を条件的に発現するベクター |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US9034652B2 (en) | 2013-03-12 | 2015-05-19 | Bio-Rad Laboratories, Inc. | Colloidal Coomassie stain |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2913052A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
| CN113307880B (zh) * | 2014-01-13 | 2025-07-04 | 希望之城公司 | 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法 |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| CN106795221B (zh) * | 2014-04-03 | 2022-06-07 | 塞勒克提斯公司 | 用于癌症免疫治疗的cd33特异性嵌合抗原受体 |
| US10611837B2 (en) * | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| WO2015179801A1 (en) | 2014-05-23 | 2015-11-26 | University Of Florida Research Foundation, Inc. | Car based immunotherapy |
| TWI719942B (zh) | 2014-07-21 | 2021-03-01 | 瑞士商諾華公司 | 使用ｃｄ３３嵌合抗原受體治療癌症 |
| BR112017005631A2 (pt) * | 2014-09-19 | 2018-06-26 | City Of Hope | células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2 |
| CA2964783C (en) * | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| US20170333480A1 (en) | 2014-11-05 | 2017-11-23 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| BR112017013981A2 (pt) | 2015-01-26 | 2018-01-02 | Cellectis | receptores antigênicos quiméricos com uma única cadeia específicos anti-cll1 (sccars) para imunoterapia de câncer |
| KR102615825B1 (ko) | 2015-03-11 | 2023-12-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 전위효소 폴리펩타이드 및 이의 용도 |
| WO2016197064A1 (en) * | 2015-06-04 | 2016-12-08 | Epstein Alan L | Lym-1 and lym-2 targeted car cell immunotherapy |
| EP3307876B1 (en) * | 2015-06-10 | 2023-09-13 | ImmunityBio, Inc. | Modified nk-92 cells for treating cancer |
| CA3025667A1 (en) | 2016-06-08 | 2017-12-14 | Intrexon Corporation | Cd33 specific chimeric antigen receptors |
-
2017
- 2017-06-07 CA CA3025667A patent/CA3025667A1/en active Pending
- 2017-06-07 KR KR1020197000376A patent/KR102469703B1/ko active Active
- 2017-06-07 US US15/616,869 patent/US11787848B2/en active Active
- 2017-06-07 EP EP17731047.1A patent/EP3468994A1/en active Pending
- 2017-06-07 IL IL263220A patent/IL263220B2/en unknown
- 2017-06-07 WO PCT/US2017/036440 patent/WO2017214333A1/en not_active Ceased
- 2017-06-07 CN CN202410513486.2A patent/CN118652336A/zh active Pending
- 2017-06-07 CN CN201780048487.2A patent/CN110191898B/zh active Active
- 2017-06-07 AU AU2017279548A patent/AU2017279548B2/en active Active
- 2017-06-07 KR KR1020227040331A patent/KR102652827B1/ko active Active
- 2017-06-07 IL IL321834A patent/IL321834A/en unknown
- 2017-06-07 KR KR1020247010094A patent/KR20240111740A/ko active Pending
- 2017-06-07 JP JP2018564239A patent/JP7591342B2/ja active Active
- 2017-06-07 SG SG11201810640RA patent/SG11201810640RA/en unknown
-
2022
- 2022-07-08 JP JP2022110311A patent/JP2022153434A/ja not_active Withdrawn
-
2023
- 2023-09-06 US US18/462,207 patent/US12559536B2/en active Active
-
2024
- 2024-06-17 JP JP2024097538A patent/JP2024138280A/ja active Pending
- 2024-07-16 AU AU2024204877A patent/AU2024204877A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517267A5 (https=) | ||
| JP2024138280A5 (https=) | ||
| US12371470B2 (en) | Compositions and methods for use of recombinant T cell receptors for direct recognition of tumor antigen | |
| JP2021525534A5 (https=) | ||
| AU2018207281B2 (en) | Modulating expression of polypeptides via new gene switch expression systems | |
| JP2021530217A5 (https=) | ||
| KR20210043562A (ko) | Ror-1 특이적 키메라 항원 수용체 및 그의 용도 | |
| JP2024023232A5 (https=) | ||
| US20220228155A1 (en) | Nr4a super-repressors and methods of use thereof | |
| CA3093919A1 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| RS62733B1 (sr) | Mnd promoter himernih antigenskih receptora | |
| KR20210021493A (ko) | Muc16 특이적 키메라 항원 수용체 및 그의 용도 | |
| JP2019512251A (ja) | Ｐｄ−１及び４−１ｂｂの融合タンパク質 | |
| JP2024036482A (ja) | Ｄａｒｉｃインターロイキン受容体 | |
| JP2020530993A (ja) | キメラ抗原受容体または改変ｔｃｒを発現し、選択的に発現されるヌクレオチド配列を含む細胞 | |
| CN113881694A (zh) | 抗磷脂酰肌醇蛋白聚糖-1-免疫抗原受体 | |
| CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
| US20240009235A1 (en) | T cell receptors directed against bob1 and uses thereof | |
| CN115315439A (zh) | 细胞 | |
| EP3374385A1 (en) | Multi-span chimeric antigen receptor | |
| RU2795198C2 (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| KR20260052956A (ko) | TGFβ 스위치 수용체, 이를 코딩하는 핵산, 이를 포함하는 세포 및 약학 조성물 | |
| RU2023106937A (ru) | Специфичные к muc16 химерные антигенные рецепторы и их применения | |
| EP4735475A2 (en) | Synthetic cytokine receptors | |
| CN121693513A (zh) | TGFβ转换受体、编码它的核酸、细胞和包含它的药物组合物 |